BlendsGLOWGLOW 70

GLOW Blend

Q: What exactly is in a GLOW vial?

The standard 70 mg vial contains 50 mg GHK-Cu (copper tripeptide-1), 10 mg BPC-157, and 10 mg TB-500 (Thymosin β4), freeze-dried together in a fixed 5 : 1 : 1 ratio by weight. It is a packaging of three known peptides, not a new molecule. Other vial sizes exist — check the label's ratio, because this page's arithmetic assumes 50/10/10.

Q: How much of each peptide is in 10 units?

At the standard mix (70 mg + 3 mL bacteriostatic water = 23,333 mcg/mL), 10 units on a U-100 insulin syringe is ≈ 2.33 mg of blend: ≈ 1.67 mg GHK-Cu, ≈ 333 mcg BPC-157, and ≈ 333 mcg TB-500. The calculator on this page shows the split for any draw, vial size, or water volume.

Q: GLOW vs KLOW vs Wolverine — which one?

They nest: [[wolverine-blend|Wolverine]] is BPC-157 + TB-500 (the injury pair, no copper peptide); GLOW adds 50 mg GHK-Cu for skin, scar, and matrix remodeling; [[klow-blend|KLOW]] adds 10 mg KPV on top of GLOW for reactive or inflamed skin. If the goal is a tendon or ligament, Wolverine or separate vials let you push BPC-157 and TB-500 harder; if the goal is skin, GLOW; if the skin is also inflamed, KLOW.

Q: Doesn't the copper in GHK-Cu destroy the BPC-157 in the vial?

No. The mechanism proposed for metal-driven peptide degradation is oxidation of sulfur-containing residues (methionine, cysteine), and BPC-157 (C62H98N16O22) contains no sulfur at all — there is nothing there for copper to attack. TB-500 does carry one methionine, so a slow oxidation in a stored, reconstituted vial is theoretically possible; nobody has published stability data on the mixed solution. Keep it refrigerated and finish it within about four weeks, the same rule as any reconstituted peptide.

Q: Is a pre-mixed blend better than buying the three separately?

A blend is convenience — one vial, one draw, a fixed recipe. Separate vials are control — you can set and change each dose independently. GLOW's ratio works well at the 10-unit convention, where BPC-157 and TB-500 sit in their own standard ranges and GHK-Cu in the upper part of its own; it works poorly if you need one component high (loading-level TB-500 for an injury) because the copper peptide climbs with it. Pick by whether your goal fits the ratio.

Q: Is GLOW an approved drug?

No. None of the three components is an approved drug for this use, no trial has ever tested the combination, and injected GHK-Cu has no human trial. BPC-157 and TB-500 are prohibited in sport by WADA. This page presents research literature and community usage only and makes no therapeutic claims.

Fixed-ratio skin & tissue-repair blend · GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg

GLOW is a pre-mixed, single-vial blend of three of the most-used repair peptides — 50 mg of the copper tripeptide GHK-Cu, 10 mg of BPC-157, and 10 mg of TB-500 (Thymosin β4) — sold as one 70 mg powder in a fixed 5 : 1 : 1 ratio. It is not a new molecule: each peptide keeps its own identity and pharmacology, and the blend simply lets one draw deliver all three in the vial's proportions. GHK-Cu leads by weight, which is why GLOW is positioned as the skin, scar, and connective-tissue member of the blend family (the copper-free pair is sold as Wolverine; adding KPV makes KLOW). The evidence for each component is separate and, for injected use, overwhelmingly preclinical; no published study has tested the three together. None of the three is an approved drug, and BPC-157 and TB-500 are prohibited in sport (WADA).

TL;DRThe whole page · in 30 seconds

Skin & scar remodeling · Collagen support · Tissue repair · Three peptides, one draw

Three repair peptides in one syringe. GLOW packs GHK-Cu's collagen-and-matrix remodeling, BPC-157's blood-supply-building repair, and TB-500's repair-cell migration into a single 70 mg vial — the blend people reach for when skin, scars, and connective tissue are the goal and three separate vials are the obstacle.

The basics

A pre-mixed powder: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 (a 5 : 1 : 1 ratio). One vial, one draw, all three every time.
The skin member of the blend family — GHK-Cu leads by weight. Wolverine is the same pair without the copper peptide; KLOW adds KPV on top.

Why people use it

Firmer, smoother-looking skin — GHK-Cu switches on collagen, elastin, and the skin's matrix in skin cells.
Heals wounds and scars with better blood supply — BPC-157 grows new vessels into the repair zone; TB-500 pulls repair cells in.
One shot instead of three — the whole recovery-and-remodeling trio in a single daily draw.
Works body-wide, not just at the needle — TB-500 and BPC-157 circulate, so the signal reaches distant tissue too.

How to run it

Dose: 10 units a day (≈ 2.3 mg of blend = 1.67 mg GHK-Cu + 333 mcg BPC-157 + 333 mcg TB-500); 5 units to start, 15 at the top
How often: Once daily
How: A small injection under the skin (belly fat) — one syringe covers all three
When: Evening — rides your overnight repair window
Cycle: 4 weeks (one vial at 10 units), then 2–4 weeks off; skin-remodeling runs go 8–12 weeks, then a 4-week break

Stacks well with

KPV — when inflammation or reactive skin is in the picture, adding KPV turns GLOW into KLOW; co-inject it or buy the four-peptide vial.
Wolverine Blend or separate BPC-157 + TB-500 vials — when the goal is an injury rather than skin, the copper-free pair lets you push those two harder without dragging the GHK-Cu load up with them.

Good to know

The ratio is the trade-off: at 10 units BPC-157 and TB-500 sit in their own standard ranges while GHK-Cu is already in the upper part of its own, and at 12 units it hits the 2 mg/day its page tops out at — GLOW isn't the vehicle for a high-dose injury protocol.
A faint blue tint is normal — that's the copper in GHK-Cu. A 10-unit dose carries about 0.26 mg of copper; injected copper skips the gut's usual regulation, so don't add copper supplements on top.
Banned in tested sport — BPC-157 and TB-500 are both on the WADA list.
Once mixed, treat the vial like its most fragile member: refrigerate and finish it within about 4 weeks (one vial at 10 units is 30 doses).

Bottom line: The one-vial answer for skin, scars, and general tissue repair — run it at 10 units a day in 4-week blocks, and switch to separate vials the moment you need to push any single peptide harder.

Molecular identity

Specs

Composition: GHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg = 70 mg per vialCross-source vendor agreement
Ratio: 5 : 1 : 1 by mass — 71.4 % GHK-Cu · 14.3 % BPC-157 · 14.3 % TB-500Calculated
Structure / class: Fixed-ratio, co-lyophilized blend of three research peptides in one vial — not a new molecule; each component keeps its own identity and pharmacologyCross-source vendor agreement
GHK-Cu (50 mg): Gly-His-Lys · Cu(II) chelate · C14H23CuN6O4+ · 402.92 g/mol · CAS 89030-95-5PubChem CID 71587328
BPC-157 (10 mg): GEPPPGKPADDAGLV (15 AA) · C62H98N16O22 · 1,419.5 g/mol · CAS 137525-51-0PubChem CID 9941957
TB-500 (10 mg): Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 AA) · C212H350N56O78S · ~4,963 g/mol · CAS 77591-33-4UniProt P62328; PubChem CID 16132341
Copper per vial: ≈ 7.9 mg elemental copper — GHK-Cu is 15.8 % copper by mass; ≈ 0.26 mg per 10-unit dose (adult oral RDA 0.9 mg/day; oral UL 10 mg/day — not an injected-copper limit)Calculated from PubChem masses
Half-life (per component): No single clock — BPC-157 clears within minutes (rat IV), TB-500 within roughly half an hour to two hours (human IV), GHK-Cu not established; the blend inherits three separate curves, not onePMID 36588717 · PMID 34346165 · PMID 20536472
Regulatory status: Not an approved drug in any form; no trial has tested the three-peptide combination; BPC-157 and TB-500 are prohibited in sport (WADA S0 / S2.3)FDA / WADA Prohibited List

Plain English

Mechanism

A blend is a packaging decision, not a new drug. GLOW is one freeze-dried powder that contains three separate peptides, so when you add water you get all three in solution together and every draw carries them in the vial's fixed proportions — 50 parts GHK-Cu to 10 parts BPC-157 to 10 parts TB-500 by weight. Nothing about that changes how each peptide works; it changes only how you measure them. The one chemistry question people raise is whether the copper in GHK-Cu attacks the other two in the vial. For BPC-157 the answer is no: the mechanism proposed for metal-driven peptide degradation is oxidation of sulfur-containing residues, and BPC-157 — C62H98N16O22 — contains no sulfur at all, so it has neither methionine nor cysteine for copper to attack. TB-500 does carry one methionine, so a slow copper-driven oxidation is at least chemically possible in a stored, reconstituted vial — a theoretical point, since nobody has published stability data on the mixed solution. The practical answer is the same one that applies to every reconstituted vial: keep it cold and use it within about four weeks.

GHK-Cu supplies the remodeling signal. It is a three-amino-acid peptide (glycine–histidine–lysine) carrying a single copper(II) ion, found naturally in human plasma. In cultured human skin fibroblasts — the cells that build connective tissue — it stimulates the synthesis of collagen, elastin, and the other components of the skin's supporting matrix, and the copper it delivers feeds lysyl oxidase, the enzyme that cross-links new collagen and elastin into durable tissue. That is the basis of its reputation in skincare. The honest caveat carries over from its own page: the robust evidence is topical and in-vitro (cells in a dish), most of the foundational reviews come from the molecule's discoverer, and there is no published human trial of injected, systemic GHK-Cu.

BPC-157 supplies the repair-and-blood-supply signal. A 15-amino-acid fragment of a protective gastric protein, it is studied for switching on angiogenesis — the growth of new blood vessels that feed a healing site — through the VEGFR2–Akt–eNOS pathway, and for speeding the migration of fibroblasts by activating their FAK/paxillin traction machinery. TB-500 (the synthetic form of Thymosin β4, the body's main actin-sequestering peptide) supplies the cell-migration signal: by controlling actin, the protein cells use to build their internal scaffolding, it speeds the movement of repair cells — fibroblasts, keratinocytes, blood-vessel-lining cells — into damaged tissue, raises VEGF, and dampens NF-κB-driven inflammation. Both are among the most extensively studied repair peptides in the preclinical literature, and both circulate systemically after a subcutaneous injection, so they act on distant tissue, not just around the injection site.

Why people combine them is the complementarity: three different levers on one repair job — the matrix and collagen quality (GHK-Cu), the blood supply and structural rebuild (BPC-157), and the arrival of repair cells (TB-500). Read the evidence level honestly, though: it is three separate, mostly animal and cell-culture evidence bases stacked side by side. No published study has tested GHK-Cu, BPC-157, and TB-500 together, in any model, at any ratio, so the synergy is reasoned from mechanism rather than shown in a trial — and the 50/10/10 recipe itself is a market convention, not a studied formulation.

Sources:PubChem CID 9941957 PubChem CID 16132341 PubChem CID 71587328 PMID 21780203 PMID 2283087 PMID 8227353 PMID 26236730 PMID 27847966 PMID 21030672 PMID 10469335 PMID 25313062 PMID 34992578

Why people reach for it

Potential benefits

GLOW is the blend people reach for when they want the skin-and-tissue trio without three vials on the shelf. Here's what draws them to it.

Firmer, smoother-looking skin — GHK-Cu's headline appeal, carried at 71 % of the vial: in cultured skin cells it switches on collagen, elastin, and the matrix that keeps skin firm, and delivers the copper that cross-links new tissue into something durable.
Scars and wounds that heal with better blood supply — BPC-157 grows new vessels into a repair zone and speeds the cells that rebuild connective tissue, while TB-500 gets repair cells moving into the wound — the pair users lean on for healing that finishes cleaner.
One draw instead of three — The practical reason the blend exists: one vial, one reconstitution, one daily injection that delivers all three peptides in a fixed ratio — fewer sticks, fewer vials to track, no separate mixing.
A whole-body repair signal, not just a local one — TB-500 and BPC-157 circulate after a subcutaneous injection, so people use GLOW for tendons, ligaments, and post-procedure recovery well away from the injection site — with GHK-Cu's matrix support riding along.
A ratio built around the standard dose — and an honest ceiling — At the community-standard 10 units, BPC-157 and TB-500 land in their own pages' standard ranges (333 mcg and ≈ 2.3 mg/week) while GHK-Cu sits in the upper part of its own at ≈ 1.67 mg. That is the ratio working as intended — and it is also why the ceiling arrives early: by 12 units GHK-Cu has reached the 2 mg/day its page tops out at, well before the other two are near theirs.

Sources:PMID 26236730 PMID 8227353 PMID 27847966 PMID 10469335 PMID 34992578

What people reach for GLOW for, drawn from what each component's research reports (predominantly cell-culture and animal work; injected GHK-Cu has no human trial) and how the blend is used — no study has tested the three together, and none of this is a proven outcome or a medical claim.

Implied timing

Best time to dose

Implied best time

Evening

Most people inject GLOW in the evening, lining all three repair signals up with the body's overnight recovery window — the same call each component's own page makes.

Overnight is when the body does most of its rebuilding — deep sleep brings the natural growth-hormone pulse, peak tissue regeneration, and the least mechanical load on healing tissue. An evening dose puts GHK-Cu's matrix signal, BPC-157's vessel-growth signal, and TB-500's cell-migration signal to work as that window opens.
None of the three has a circadian rule of its own: BPC-157 clears the blood in minutes (rat IV) and TB-500 in about half an hour to two hours (human IV), so the value is in the repair signal each leaves behind, and GHK-Cu's remodeling effect is a slow signal rather than a stimulant. That makes consistency matter more than the exact hour.
Because the blend is one daily draw, there is no split schedule to juggle — a single consistent evening slot is the whole timing plan. Morning works if evening is impractical; the peptides don't care, the habit does.

No study establishes an ideal time of day for GLOW or for any of its three components — this is reasoned from their mechanisms and how they're used. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for GLOW the lean is evening, to align with overnight repair.

Sources:PMID 36588717 PMID 34346165

How to run it

Dosing & protocol

GLOW is dosed here as one subcutaneous injection a day, measured as total blend on a U-100 insulin syringe — the form it's sold in and the route every calculator on this site is built for. The defining fact of a blend is that you dose all three peptides with one number: pick the units and the ratio decides how much of each you get. The tiers below are built from the three component pages' own ranges so you can see, at each draw size, what every peptide is doing relative to its own convention. Read it as a map of how people actually run GLOW — not a validated prescription.

Community convention, not trial-proven: no study has tested the GHK-Cu + BPC-157 + TB-500 combination, injected GHK-Cu has no human trial, and BPC-157 and TB-500's systemic evidence is preclinical. None of the three is FDA-approved. Every number here is a usage pattern assembled from the component pages — not a medical recommendation.

Tiered dose ranges (total blend per draw)

Standard mix: 70 mg vial + 3 mL bacteriostatic water = 23,333 mcg/mL, so 1 unit on a U-100 syringe ≈ 233 mcg of blend (≈ 167 mcg GHK-Cu + 33 mcg BPC-157 + 33 mcg TB-500).

Low / first week — 5 units (≈ 1.2 mg):: ≈ 833 mcg GHK-Cu + 167 mcg BPC-157 + 167 mcg TB-500 once daily. BPC-157 (150–250 mcg) and TB-500 (≈ 1.2 mg/week at this daily rate) sit in their own pages' low bands; GHK-Cu at 833 mcg is already just above its 500–750 mcg low band, short of its 1 mg standard. Used to check tolerance, or as a light maintenance dose for skin goals.
Standard — 10 units (≈ 2.3 mg):: ≈ 1.67 mg GHK-Cu + 333 mcg BPC-157 + 333 mcg TB-500 once daily — the community convention, and the draw the whole ratio is built around: BPC-157 sits mid-band in its own 250–500 mcg standard range, GHK-Cu lands in the upper part of its own range (its page calls 1 mg standard and 1.5–2 mg the high band, so 1.67 mg is a high-band dose), and TB-500 at ≈ 2.3 mg/week, which is exactly its once-weekly maintenance band delivered as small daily doses.
High / ceiling — 15 units (≈ 3.5 mg):: ≈ 2.5 mg GHK-Cu + 500 mcg BPC-157 + 500 mcg TB-500 once daily. BPC-157 reaches its active-injury dose and TB-500 ≈ 3.5 mg/week (between maintenance and loading) — but GHK-Cu is now above the 2 mg/day its own page tops out at, with no data showing added benefit past 1 mg. That copper load, not the other two peptides, is why the blend's ceiling sits here. Users who see 20-unit protocols online are running ≈ 3.3 mg GHK-Cu/day; if the goal is an injury that needs loading-level BPC-157 or TB-500, the honest move is separate vials (or Wolverine) rather than more GLOW.

Subcutaneous administration

GLOW is injected into subcutaneous fat; because it's one draw a day, site rotation and a consistent evening slot are the only execution choices.

Injection site:: Abdomen (a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites daily — copper-containing solutions are the ones people most often report a little site irritation from, and rotation is the fix. Injecting near a scar or healing area is a common user preference, not a requirement: BPC-157 and TB-500 circulate systemically.
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. At the standard 70 mg + 3 mL mix: 5 units ≈ 1.2 mg · 10 units ≈ 2.3 mg · 15 units ≈ 3.5 mg of blend. The calculator on this page shows what each draw contains of every component, for any vial size or water volume.
Time of day:: Evening — see Best time to dose above. There is no circadian constraint, so a consistent daily time matters more than the exact hour; morning is fine if evening doesn't fit.
Food window:: Subcutaneous injection; none of the three competes with food for absorption. Inject independent of meals.

Cycle & washout

One vial at the standard draw is a natural 4-week block — the shortest of the three components' cycles (BPC-157's 4–6 weeks) sets the floor, GHK-Cu's 8–12-week remodeling runs set the ceiling.

Standard block:: 4 weeks at 10 units/day — one 70 mg vial covers it with a couple of doses to spare (30 doses in the vial, 28 in the block). Then 2–4 weeks off. The most common way GLOW is run, and the cleanest: one vial, one block, reassess.
Skin-remodeling run:: 8–12 weeks of continuous daily use (two to three vials) for scar, texture, and post-procedure remodeling goals, mirroring the GHK-Cu page's standard cycle; then a 4-week break. Many taper to 5 units for the back half rather than stopping outright.
Washout:: 2–4 weeks off after a 4-week block; 4 weeks after a long run. Reassess the skin or tissue goal during the break — photographs work better than memory for skin — before deciding whether to repeat.
Loading, if an injury is the reason:: GLOW is not built for TB-500 loading (that is 2–2.5 mg twice weekly, 4–5 mg/week). Some add one separate 2–2.5 mg TB-500 dose per week on top of 10 units of GLOW for the first 4–6 weeks of an acute injury; the alternative is to run Wolverine or separate vials for the injury and keep GLOW for the skin goal.

Reconstitution at a glance

The on-page calculator does this live and splits every draw into its three components; the quick reference for the standard 70 mg vial:

Mixing (3 mL — the common convention):: 70 mg vial + 3 mL bacteriostatic water = 23,333 mcg per mL (≈ 23.3 mg/mL). On a 100-unit (1 mL) insulin syringe: 5 units ≈ 1,167 mcg · 10 units ≈ 2,333 mcg · 15 units ≈ 3,500 mcg of blend. Each unit ≈ 167 mcg GHK-Cu + 33 mcg BPC-157 + 33 mcg TB-500.
Mixing (2 mL — the compact alternative):: 70 mg + 2 mL = 35,000 mcg/mL, so 1 unit ≈ 350 mcg of blend and the standard 2.33 mg dose becomes ≈ 6.7 units. The 3 mL mix simply lands the common dose on a round 10-unit mark; either works — just don't switch water volume mid-vial without redoing the math.
Why the split matters more than the total:: The syringe measures total blend, but each component's safety and dose logic lives on its own page. The calculator's 'this dose contains' readout is the number to compare against those pages. The split assumes the standard 50/10/10 recipe; if your label lists a different ratio, this page's arithmetic doesn't apply to it.
Copper arithmetic:: GHK-Cu is 15.8 % copper by mass (Cu 63.55 ÷ GHK-Cu 402.92 g/mol), so a 70 mg vial holds ≈ 7.9 mg of elemental copper and a 10-unit dose delivers ≈ 0.26 mg — under a third of the adult oral RDA (0.9 mg/day) and far under the oral upper limit (10 mg/day). The comparison is context only, and it flatters the injected figure: those limits govern copper eaten and regulated by the gut, only a fraction of an oral dose is absorbed at all, and there is no established safety threshold for copper injected past that regulation.

Sources:PMID 8227353 PMID 26236730 PMID 27847966 PMID 36588717 PMID 10469335 PMID 34346165 PubChem CID 71587328 NIH ODS

Substrate the signal needs

Nutritional cofactor precision

GLOW's three levers are matrix remodeling (GHK-Cu), angiogenesis and structural rebuild (BPC-157), and repair-cell migration (TB-500). The cofactors follow those levers — supply the collagen the remodeling signal builds with, feed the nitric-oxide system the vessel-growth signal runs on, and, uniquely for this blend, manage copper the right way round: GLOW already delivers it.

Reasoned from the three components' mechanisms plus general connective-tissue nutrition — not a GLOW cofactor study. Supplement doses are common community ranges, not blend-specific findings.

Supply the collagen substrate

All three peptides signal for new tissue; this group supplies the raw material that signal builds with.

Hydrolyzed collagen + vitamin C:: 10–15 g hydrolyzed collagen peptides with 500 mg vitamin C, ~30–60 min before activity or in the evening with the injection. Vitamin C is the required cofactor for prolyl and lysyl hydroxylases — the enzymes that lock collagen into its stable triple helix — so without it, GHK-Cu's collagen signal and BPC-157's repair signal have nothing finished to build with.
Glycine & proline:: The bulk of the collagen sequence. Adequate protein (1.6–2.0 g/kg/day) keeps the pool replete; a 3–5 g glycine supplement is a common addition during a remodeling run.

Balance the copper — GLOW already supplies it

This is the cofactor question that runs the opposite way from most stacks: a 10-unit dose delivers ≈ 0.26 mg of copper by injection, past the gut's usual regulation.

No added copper:: Skip copper supplements while running GLOW — the blend delivers copper directly, and the lysyl oxidase cross-linking step it feeds is well served by the peptide plus a normal diet (organ meats, shellfish, nuts, legumes). The usual 1–2 mg copper pairing that BPC-157 and TB-500 users add alongside zinc is already covered here.
Zinc 15–30 mg — keep it moderate:: Zinc drives the matrix metalloproteinases that clear old matrix before new collagen is laid down, so it still belongs in a remodeling protocol. But zinc and copper compete for absorption, and high-dose zinc (≈ 60 mg/day for weeks) depletes copper status — while the blend is adding copper by a route the gut can't regulate. Keep zinc at 15–30 mg with food and don't run it high; the balance, not the dose, is the point.

Amplify the vessel-growth and perfusion work

BPC-157 acts through the VEGFR2–Akt–eNOS axis and TB-500 raises VEGF; both depend on nitric oxide for the new vessels to dilate and perfuse the repair.

L-arginine or L-citrulline:: L-arginine 3–6 g/day or L-citrulline 3 g/day (citrulline converts more efficiently and skips first-pass gut degradation). Arginine is the direct substrate for eNOS, the enzyme that makes nitric oxide — the same pathway BPC-157 is activating. Morning or pre-workout; skip if blood pressure runs low.

Sources:PMC2589959 PMID 9587142 PMC5793244 NIH ODS PMID 27847966 PMID 34992578

Combinations + timing

Stacking notes + timing windows

GLOW already stacks three complementary repair mechanisms, so the useful additions come from a different angle entirely — inflammation control, a growth-hormone backdrop, or simply un-fixing the ratio when one component needs to go higher than the blend allows.

User combinations reasoned from complementary mechanisms — not regimens studied head-to-head, and the blend itself has never been studied. Doses are community convention; "reached for" describes where users go, not a proven indication.

GLOW + KPV (= KLOW)

The most common addition — an anti-inflammatory brake on top of the three repair signals.

Why it works:: KPV is carried inside gut and immune cells and turns down NF-κB, the master inflammatory switch, so the repair GLOW signals for happens in calmer tissue with less scarring. It's a different lever (calm) from the blend's three (remodel, rebuild, migrate) — not the same one twice. Pre-mixed, this exact combination is sold as KLOW (80 mg: the GLOW recipe plus 10 mg KPV).
The protocol:: GLOW 10 units daily + KPV 300–500 mcg subcutaneously once daily, co-drawn or as a second nearby site — or switch to a KLOW vial, where 10 units at the 3 mL mix delivers the same GHK-Cu/BPC-157/TB-500 split plus ≈ 333 mcg KPV.
Outcome:: Reached for on reactive or inflamed skin, post-procedure redness, and any repair goal where inflammation is part of the problem.

GLOW + separate BPC-157 / TB-500 top-ups

Un-fixing the ratio — when an injury needs more of the two systemic repair peptides than 10 units of GLOW delivers.

Why it works:: The blend's ceiling is set by GHK-Cu, not by BPC-157 or TB-500. Adding those two from their own vials raises the repair signals an injury actually wants — BPC-157 above its 333 mcg from the blend and TB-500 to a loading-level 4–5 mg/week — without pushing the copper peptide past 2 mg/day.
The protocol:: GLOW 10 units daily, plus BPC-157 250 mcg daily (bringing the total to ≈ 583 mcg — just over the 500 mcg/day its own page tops out at, so treat 250 mcg as the ceiling on the top-up rather than a starting point) and/or one separate 2–2.5 mg TB-500 injection per week for the first 4–6 weeks of an acute injury. Rotate sites; the top-ups can be co-drawn with the GLOW dose. Many simply run Wolverine for the injury instead and keep GLOW for the skin goal.
Outcome:: Reached for when a tendon, ligament, or post-surgical recovery is the real target and skin remodeling is the bonus, not the point.

GLOW + CJC-1295 / Ipamorelin

A growth-hormone backdrop under the local repair signals — a hormonal lever the blend doesn't have.

Why it works:: CJC-1295 (GHRH receptor) and Ipamorelin (ghrelin receptor) raise the body's own overnight growth-hormone pulse, and GH/IGF-1 drive whole-body protein synthesis and skin thickness — a systemic anabolic backdrop, while GLOW works the local repair chemistry. Different axis entirely, so it's additive rather than redundant.
The protocol:: GLOW 10 units in the evening; the GH pair on its own schedule — typically 100 mcg CJC-1295 (no-DAC) + 200–300 mcg Ipamorelin at bedtime on an empty stomach, or the pre-mixed CJC-1295 / Ipamorelin blend. Keep the GH pair fasted; GLOW doesn't care about food.
Outcome:: Reached for on body-composition-plus-skin goals and slower post-injury recoveries where a GH backdrop is wanted alongside the repair trio.

Sources:PMID 34992578 PMID 27847966 PMID 8227353

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

This dose contains

GHK-Cu1.67 mg
BPC-157333 mcg
TB-500333 mcg

Fixed ratio — every draw carries all of the vial's peptides in the same proportions; only the total changes.

Volume per dose: 0.1 mL
Doses per vial: 30
Concentration: 23.33 mg/mL

One vial lasts

Daily: 30 days
Every other day: 60 days
5×/week: 42 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no safety study of GLOW itself, so the safety picture is the three component pictures laid side by side — and none of them is a human injectable dataset for this use. BPC-157's formal animal toxicology (mice, rats, rabbits, dogs) reported good tolerability with no lethal dose found and only a small, reversible creatinine dip in dogs at high doses. Full-length Thymosin β4 was well tolerated in human Phase I intravenous trials up to 1,260 mg with no dose-limiting toxicity, and its Phase III eye-drop trial reported mostly mild eye-related effects. GHK-Cu's tolerability data come from small, often industry-run topical studies; there is no controlled human safety dataset for injected GHK-Cu at all.

Two cautions are specific to running the three as one fixed-ratio vial. First, copper: GHK-Cu is 15.8 % copper by mass, so a 10-unit dose injects about 0.26 mg of a redox-active metal past the gut, where copper intake is normally regulated. That is a fraction of the adult oral RDA, but the oral limits are not an injected-copper threshold, and there is no human dataset that establishes one — chronic high-dose systemic copper exposure is a theoretical pro-oxidant concern, not a documented harm, and it is the reason the blend's practical ceiling is set by the GHK-Cu load rather than by the other two peptides. Second, you cannot adjust one component without moving the others: if any single peptide gives you a reaction, the only lever is to lower the whole dose or leave the blend for separate vials.

The cautions that carry over unchanged: because TB-500 promotes both new blood-vessel growth and cell migration — the same activities that can feed a tumor — its relationship to cancer growth and metastasis is unresolved in the literature, so people with an active or recent cancer generally avoid it (and therefore GLOW). BPC-157 and TB-500 are both prohibited in sport by WADA at all times. Injection-site irritation is the most common practical complaint users report with copper-containing blends; it is community-reported, not studied, and site rotation is the usual fix. This safety picture is preclinical and, for GHK-Cu, largely topical — none of it is human trial evidence for injected use.

Sources:PMID 32334036 PMID 34346165 PMID 20536472 PMID 36613994 PMID 34992578 PMID 21780203 NIH ODS

As reported in literature

Research dosing ranges

There is no research dose for GLOW because there is no research on GLOW: no published study has tested GHK-Cu, BPC-157, and TB-500 together in any model. What exists is three separate evidence bases, and the practical figures above lean on each component page's cited ranges. The rows below pull the load-bearing study doses from those pages so the evidence behind each component is visible here — shown separately so research data is never mistaken for a human dose. Mostly rodent; per kilogram of body weight (1 kg ≈ 2.2 lb) where the studies report it that way. Note the route mismatch for GHK-Cu: its human and clinical use is topical, and the only injected animal data is local intra-wound injection, not systemic dosing.

Dose	Route	Model	Outcome	Sources:
Any	Subcutaneous	— no study of the three-peptide blend	No published study has tested GHK-Cu + BPC-157 + TB-500 together; the 50/10/10 vial ratio is a market convention, not a studied formulation
Local intra-wound injection	Injected (local, intra-wound)	Rat — experimental wound chambers (GHK-Cu)	Locally injected GHK-Cu stimulated connective-tissue/collagen accumulation; local delivery, not systemic dosing	PMID 8227353
Low-percentage facial cream (<1%)	Topical	Human — 12-week cosmetic study (GHK-Cu; industry-sponsored)	Reported improvements in skin firmness, clarity, and density vs comparators; low-tier evidence	AAD Annual Meeting 2002 (conference presentation)
10 µg/kg	Intraperitoneal	Rat (ligament) — BPC-157	Ligament healing + biomechanics	PMID 20225319
20–500 µg/kg	IV & IM	Rat (PK) — BPC-157	Pharmacokinetics (n=6/group)	PMID 36588717
Topical / IP	Topical / IP	Rat (dermal wound) — TB-500	+42% re-epithelialization (d4), +61% (d7)	PMID 10469335
0.05–25 µg/kg	Intravenous	Human (Phase I PK/safety, n=84) — TB-500	Dose-proportional PK; no dose-limiting toxicity	PMID 34346165

Quick answers

Frequently asked

What exactly is in a GLOW vial?

The standard 70 mg vial contains 50 mg GHK-Cu (copper tripeptide-1), 10 mg BPC-157, and 10 mg TB-500 (Thymosin β4), freeze-dried together in a fixed 5 : 1 : 1 ratio by weight. It is a packaging of three known peptides, not a new molecule. Other vial sizes exist — check the label's ratio, because this page's arithmetic assumes 50/10/10.

How much of each peptide is in 10 units?

At the standard mix (70 mg + 3 mL bacteriostatic water = 23,333 mcg/mL), 10 units on a U-100 insulin syringe is ≈ 2.33 mg of blend: ≈ 1.67 mg GHK-Cu, ≈ 333 mcg BPC-157, and ≈ 333 mcg TB-500. The calculator on this page shows the split for any draw, vial size, or water volume.

GLOW vs KLOW vs Wolverine — which one?

They nest: Wolverine is BPC-157 + TB-500 (the injury pair, no copper peptide); GLOW adds 50 mg GHK-Cu for skin, scar, and matrix remodeling; KLOW adds 10 mg KPV on top of GLOW for reactive or inflamed skin. If the goal is a tendon or ligament, Wolverine or separate vials let you push BPC-157 and TB-500 harder; if the goal is skin, GLOW; if the skin is also inflamed, KLOW.

Doesn't the copper in GHK-Cu destroy the BPC-157 in the vial?

No. The mechanism proposed for metal-driven peptide degradation is oxidation of sulfur-containing residues (methionine, cysteine), and BPC-157 (C62H98N16O22) contains no sulfur at all — there is nothing there for copper to attack. TB-500 does carry one methionine, so a slow oxidation in a stored, reconstituted vial is theoretically possible; nobody has published stability data on the mixed solution. Keep it refrigerated and finish it within about four weeks, the same rule as any reconstituted peptide.

Is a pre-mixed blend better than buying the three separately?

A blend is convenience — one vial, one draw, a fixed recipe. Separate vials are control — you can set and change each dose independently. GLOW's ratio works well at the 10-unit convention, where BPC-157 and TB-500 sit in their own standard ranges and GHK-Cu in the upper part of its own; it works poorly if you need one component high (loading-level TB-500 for an injury) because the copper peptide climbs with it. Pick by whether your goal fits the ratio.

Is GLOW an approved drug?

No. None of the three components is an approved drug for this use, no trial has ever tested the combination, and injected GHK-Cu has no human trial. BPC-157 and TB-500 are prohibited in sport by WADA. This page presents research literature and community usage only and makes no therapeutic claims.

Primary sources

References

PubChem CID 71587328PubChem CID 71587328 (Prezatide copper / GHK-Cu complex; C14H23CuN6O4+, MW 402.92; Cu(II) chelate)
PubChem CID 9941957PubChem CID 9941957 (BPC-157; C62H98N16O22 — no sulfur, so no methionine/cysteine for copper to attack)
PubChem CID 16132341PubChem CID 16132341 (Thymosin β4 / TB-500; one methionine, no cysteine)
PMID 2283087Stadtman — metal-catalyzed oxidation of proteins (copper/iron attack sulfur and other residues), Free Radic Biol Med 1990
PMID 21780203Hureau et al. — redox chemistry of the Cu(II) complexes of GHK and DAHK (copper is reactive, not inert), Chem Eur J 2011
PMID 8227353Maquart et al., J Clin Invest 1993 (in-vivo: locally injected GHK-Cu stimulates connective-tissue/collagen accumulation in rat wound chambers)
PMID 26236730Pickart, Vasquez-Soltero & Margolina, Biomed Res Int 2015 (regenerative & protective actions of GHK in skin — review)
AAD Annual Meeting 2002 (conference presentation)Leyden, Stephens, Finkey, Appa & Barkovic — facial & periorbital GHK-Cu cream cosmetic studies (industry-sponsored; no PMID located)
PMID 27847966J. Mol. Med. 2017 (BPC-157 — VEGFR2/angiogenesis)
PMID 21030672J. Appl. Physiol. 2011 (BPC-157 — fibroblast FAK/paxillin migration)
PMID 20225319J. Orthop. Res. 2010 (BPC-157 — rat ligament healing)
PMID 36588717Front. Pharmacol. 2022 (BPC-157 — rat/dog pharmacokinetics)
PMID 32334036Regul. Toxicol. Pharmacol. 2020 (BPC-157 — formal animal safety/toxicology)
PMID 10469335J Invest Dermatol 1999 (Tβ4 wound healing, rat)
PMID 25313062PNAS 2014 (structural basis, Tβ4–actin)
PMID 34992578Front. Endocrinol. 2021 (Tβ4 function & application review)
PMID 34346165J Cell Mol Med 2021 (Phase I rhTβ4, IV PK/safety)
PMID 20536472Phase I synthetic Tβ4, IV PK/safety
PMID 36613994RGN-259 Phase III neurotrophic keratopathy (Tβ4 eye drops)
PMC2589959Ascorbate & collagen (review)
PMID 9587142Rucker et al. 1998 (copper and lysyl oxidase cross-linking)
PMC5793244Zinc in wound healing (review)
NIH ODSNIH Office of Dietary Supplements — Copper fact sheet for health professionals (adult RDA 900 mcg/day; UL 10 mg/day; high-dose zinc depletes copper)
WADAWADA Prohibited List (BPC-157 S0; Thymosin β4 S2.3 — prohibited at all times)

Reviewed by Ki Researcher Team · Research use only · Not medical advice · Updated 2026-09-01